Certara, Inc. (NASDAQ:CERT – Get Free Report) has received an average recommendation of “Hold” from the eight brokerages that are covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $15.92.
A number of equities research analysts recently weighed in on CERT shares. Robert W. Baird dropped their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. Barclays reduced their target price on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, November 7th.
Read Our Latest Report on Certara
Institutional Trading of Certara
Certara Price Performance
Shares of Certara stock opened at $13.89 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm’s 50-day simple moving average is $11.36 and its 200-day simple moving average is $11.86. Certara has a twelve month low of $9.41 and a twelve month high of $19.87. The firm has a market cap of $2.24 billion, a P/E ratio of -69.45, a price-to-earnings-growth ratio of 9.77 and a beta of 1.52.
Certara (NASDAQ:CERT – Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The firm had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. During the same period last year, the firm posted $0.06 EPS. The firm’s quarterly revenue was up 10.7% on a year-over-year basis. As a group, research analysts expect that Certara will post 0.28 EPS for the current fiscal year.
Certara Company Profile
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.
Recommended Stories
- Five stocks we like better than Certara
- Quiet Period Expirations Explained
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Insider Trading – What You Need to Know
- 3 Steel Stocks Soaring After Tariff Announcements
- Trading Halts Explained
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.